Get the latest Science News and Discoveries

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of NSCLC

NSCLC

Photo of Lorlatinib

Lorlatinib

Related news:

Radiation Oncology trials using PET with FDG uptake among NSCLC patients

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC

Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations

« High-Entropy Alloys: Islands Without Structure Inside Metal Alloys for Tougher Materials

Rocks Show Mars Once Felt Like Iceland: Crater Study Offers Window on Temperatures 3.5 Billion Years Ago »